September 16th 2024
New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.
Dr. Tran on enzalutamide plus salvage radiation therapy in biochemically recurrent prostate cancer
January 30th 2023The phase 2 SALV-ENZA trial explored whether the addition of enzalutamide to salvage radiation therapy could improve outcomes in patients with high-risk, PSA-recurrent prostate cancer after radical prostatectomy.